On February 12, 2025, at noon Eastern Time, Genmab A/S held their Q4 2024 Earnings Conference Call.
Representatives from the company included CEO Jan van de Winkel, EVP and Chief Commercial Officer Brad Bailey, CFO Anthony Pagano, Chief Medical Officer Tahamtan Ahmadi, and Chief Development Officer Judith Klimovsky.
The conference call attracted several analysts, such as Jonathan Chang from Leerink Partners, Paul Jeng from Guggenheim Securities, Asthika Goonewardene from Truist Securities, Yifeng Liu from HSBC, Xian Deng from UBS, Yaron Werber from TD Securities, Matthew Phipps from William Blair, Qize Ding from Redburn Atlantic, Justin Smith from Bernstein, Vikram Purohit from Morgan Stanley, and Rajan Sharma from Goldman Sachs.
As the call began, the operator welcomed everyone to the session, reminding all participants that the call was being recorded. Participants were cautioned that some statements made during the call might contain forward-looking language, with terms like “believes,” “anticipates,” “plans,” or “expects.” These statements carry inherent risks, as actual results might vary significantly, for instance, due to delays or setbacks in development projects. Genmab does not commit to updating forward-looking statements to reflect actual outcomes unless required by law.
Attendees were also informed that their personal data might be retained by Genmab, as part of its Investor Relations efforts, to keep investors informed about the company’s progress. More details on this can be found on Genmab’s website, which also hosts their comprehensive privacy policy.
Kicking off the proceedings, CEO Jan van de Winkel extended a warm welcome to everyone joining the call, setting the stage to delve into the financial performance for the year ending December 31, 2024. Alongside him were CFO Anthony Pagano and Chief Commercial Officer Brad Bailey, ready to share insights. For the question and answer portion of the call, these key executives would be available to address any inquiries from participants.
